Physician profile
Mary P Bui
NPI 1841225224
$1,653.45
in general payments reported to CMS, 2019-2025
20 companies · $291 in 2025
The $291 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.77 · 2020: $24.70 · 2021: $88.06 · 2022: $290 · 2023: $294 · 2024: $602 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.26 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $333.98 | 2019-2025 | Farxiga, Saphnelo |
| Akebia Therapeutics INC | $271.57 | 2019-2025 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $267.23 | 2022-2025 | Lupkynis |
| Bard Peripheral Vascular, INC. | $129.33 | 2022-2025 | Pristine, Covera, Fluency Endovascular Stent Graft |
| Fresenius USA Marketing, INC. | $87.31 | 2021-2024 | Velphoro |
| Glaxosmithkline, LLC. | $76.54 | 2021-2023 | Benlysta |
| Calliditas Therapeutics US INC. | $72.08 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $65.35 | 2022-2024 | Veltassa |
| Opko Pharmaceuticals, LLC | $59.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.25 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $44.83 | 2020-2022 | |
| Biotronik INC. | $38.66 | 2024 | Pulsar-18 T3 |
| Kestra Medical Technology Services, INC. | $22.78 | 2023 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.48 | 2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $19.50 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.27 | 2021 | |
| Lemaitre Vascular, INC. | $18.08 | 2022 | |
| Lilly USA, LLC | $17.18 | 2023 | Jardiance |
| Boston Scientific Corporation | $16.31 | 2023 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $15.44 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.